AstraZeneca PLC (AZN) Stock Price
AZNStock
$165.41−0.94%52W
Market Cap$256.54B
P/E25.67x
PEG Ratio1.14
Div yield2.30%
Beta1.27
AZN Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-25.62%
Price vs S&P 500 (4W)0.42%
PEG Ratio1.14
VGM Score58.77
P/E Ratio (Annual)25.67x
Indicated Dividend Yield (Annual)2.30%
AZN Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $1.25 | $1.31 | +4.85%(+$0.06) | |
| Q1 2026 | $1.27 | $1.29 | +1.43%(+$0.02) |
AZN Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.14
4.14
4.17
4.14
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
| BMYBristol-Myers Squibb Co. | B | B | B | 2.5x | 3.1% | 71.7% | — | $59.75 |
About AstraZeneca PLC
AstraZeneca is a multinational pharmaceutical company formed in 1999 through the merger of Sweden's Astra and UK-based Zeneca. The company develops and markets branded drugs across oncology (over 40% of revenue), cardiovascular and metabolic diseases (20%+), rare diseases, and respiratory and immunology. Its revenue is geographically diversified, with approximately one-third of sales derived from the United States and the remainder from international markets.